The relationship between UGT1A1 gene & various diseases and prevention strategies.

IF 3.4 2区 医学 Q2 PHARMACOLOGY & PHARMACY
Drug Metabolism Reviews Pub Date : 2022-02-01 Epub Date: 2021-11-22 DOI:10.1080/03602532.2021.2001493
Dan Liu, Qi Yu, Qing Ning, Zhongqiu Liu, Jie Song
{"title":"The relationship between <i>UGT1A1</i> gene & various diseases and prevention strategies.","authors":"Dan Liu,&nbsp;Qi Yu,&nbsp;Qing Ning,&nbsp;Zhongqiu Liu,&nbsp;Jie Song","doi":"10.1080/03602532.2021.2001493","DOIUrl":null,"url":null,"abstract":"<p><p>UDP-glucuronyltransferase 1A1 (UGT1A1) is a member of the Phase II metabolic enzyme family and the only enzyme that can metabolize detoxified bilirubin. Inactivation and very low activity of UGT1A1 in the liver can be fatal or lead to lifelong Gilbert's syndrome (GS) and Crigler-Najjar syndrome (CN). To date, more than one hundred UGT1A1 polymorphisms have been discovered. Although most UGT1A1 polymorphisms are not fatal, which diseases might be associated with low activity UGT1A1 or UGT1A1 polymorphisms? This scientific topic has been studied for more than a hundred years, there are still many uncertainties. Herein, this article will summarize all the possibilities of <i>UGT1A1</i> gene-related diseases, including GS and CN, neurological disease, hepatobiliary disease, metabolic difficulties, gallstone, cardiovascular disease, Crohn's disease (CD) obesity, diabetes, myelosuppression, leukemia, tumorigenesis, etc., and provide guidance for researchers to conduct in-depth study on <i>UGT1A1</i> gene-related diseases. In addition, this article not only summarizes the prevention strategies of <i>UGT1A1</i> gene-related diseases, but also puts forward some insights for sharing.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 1","pages":"1-21"},"PeriodicalIF":3.4000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03602532.2021.2001493","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 4

Abstract

UDP-glucuronyltransferase 1A1 (UGT1A1) is a member of the Phase II metabolic enzyme family and the only enzyme that can metabolize detoxified bilirubin. Inactivation and very low activity of UGT1A1 in the liver can be fatal or lead to lifelong Gilbert's syndrome (GS) and Crigler-Najjar syndrome (CN). To date, more than one hundred UGT1A1 polymorphisms have been discovered. Although most UGT1A1 polymorphisms are not fatal, which diseases might be associated with low activity UGT1A1 or UGT1A1 polymorphisms? This scientific topic has been studied for more than a hundred years, there are still many uncertainties. Herein, this article will summarize all the possibilities of UGT1A1 gene-related diseases, including GS and CN, neurological disease, hepatobiliary disease, metabolic difficulties, gallstone, cardiovascular disease, Crohn's disease (CD) obesity, diabetes, myelosuppression, leukemia, tumorigenesis, etc., and provide guidance for researchers to conduct in-depth study on UGT1A1 gene-related diseases. In addition, this article not only summarizes the prevention strategies of UGT1A1 gene-related diseases, but also puts forward some insights for sharing.

UGT1A1基因与多种疾病的关系及预防策略
UDP-glucuronyltransferase 1A1 (UGT1A1)是II期代谢酶家族的一员,也是唯一能代谢解毒胆红素的酶。肝脏中UGT1A1的失活和极低的活性可能是致命的,或导致终生的吉尔伯特综合征(GS)和克里格勒-纳贾尔综合征(CN)。迄今为止,已经发现了100多个UGT1A1多态性。虽然大多数UGT1A1多态性不是致命的,但哪些疾病可能与低活性UGT1A1或UGT1A1多态性相关?这一科学课题已经研究了一百多年,但仍有许多不确定因素。本文将总结UGT1A1基因相关疾病的所有可能性,包括GS和CN、神经系统疾病、肝胆系统疾病、代谢困难、胆结石、心血管疾病、克罗恩病(CD)肥胖、糖尿病、骨髓抑制、白血病、肿瘤发生等,为研究人员深入研究UGT1A1基因相关疾病提供指导。此外,本文不仅总结了UGT1A1基因相关疾病的预防策略,还提出了一些见解供大家分享。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Metabolism Reviews
Drug Metabolism Reviews 医学-药学
CiteScore
11.10
自引率
1.70%
发文量
21
审稿时长
1 months
期刊介绍: Drug Metabolism Reviews consistently provides critically needed reviews of an impressive array of drug metabolism research-covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species. Additionally, the journal offers new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信